New Chapter Update: Clostridium difficile Infection

patti grota headshot 2

In our latest content update, Jason E. Bowling, MD revisits our chapter on Clostridium difficile infection (CDI), one of the most common and costly healthcare-associated infections and one with a unique epidemiological association with prior antimicrobial treatment. Important new coverage includes:

  • The latest treatment guidelines from the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA)
  • New evaluation of the diagnostic effectiveness of nucleic acid amplification tests (NAATs) and its impact on reported CDI rates
  • Discussion of bezlotoxumab, an alternative therapy for recurrent CDI approved by the FDA in 2016
  • The potential role of UV-C devices as a disinfection modality in terminal room cleaning

The ATO continues to support concurrent review and updates of important chapters based on infection prevention trends and issues, as well as developing new chapters. Other recent chapter updates include:

APIC is excited to hear your thoughts about the revised chapter, as well as the entire ATO platform. Your views are critical to APIC’s success in providing the resources that you need to flourish as an IP. Please email us with any feedback at


Patti G. Grota, PhD, RN, CNS-M-S, CIC, FAPIC